Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations

Jae Baek¹, Dwight H Owen², Robert E Merritt³, Konstantin Shilo⁴, Gregory A Otterson², Desmond M D'Souza³, David P Carbone², Peter J Kneuertz⁵

Affiliations

¹ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
² Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
³ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
⁴ Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
⁵ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH. Electronic address: peter.kneuertz@osumc.edu.

PMID: 32184051
DOI: 10.1016/j.cllc.2020.02.016

Case Reports

Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations

Jae Baek et al. Clin Lung Cancer. 2020 Jul.

. 2020 Jul;21(4):e265-e269.

doi: 10.1016/j.cllc.2020.02.016. Epub 2020 Feb 25.

Authors

Jae Baek¹, Dwight H Owen², Robert E Merritt³, Konstantin Shilo⁴, Gregory A Otterson², Desmond M D'Souza³, David P Carbone², Peter J Kneuertz⁵

Affiliations

¹ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
² Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
³ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
⁴ Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH.
⁵ Division of Thoracic Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; Ohio State University Comprehensive Cancer Center- James and Solove Research Institute, Columbus, OH. Electronic address: peter.kneuertz@osumc.edu.

PMID: 32184051
DOI: 10.1016/j.cllc.2020.02.016

No abstract available

Keywords: Immune checkpoint therapy; Immunotherapy; Lobectomy; Minimally invasive; Non–small-cell lung cancer.

PubMed Disclaimer

Cited by

Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.
Deng H, Liang H, Chen J, Wang W, Li J, Xiong S, Cheng B, Li C, Chen Z, Wang H, Zheng J, Guo Z, He J, Liang W. Deng H, et al. Transl Lung Cancer Res. 2022 Dec;11(12):2364-2381. doi: 10.21037/tlcr-22-439. Transl Lung Cancer Res. 2022. PMID: 36636407 Free PMC article.
Correspondence Regarding "Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study".
Takada K, Takamori S. Takada K, et al. JTO Clin Res Rep. 2023 Jul 5;4(8):100548. doi: 10.1016/j.jtocrr.2023.100548. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37554348 Free PMC article. No abstract available.
Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery.
Takenaka M, Tanaka F, Kajiyama K, Manabe T, Yoshimatsu K, Mori M, Kanayama M, Taira A, Kuwata T, Nawata A, Kuroda K. Takenaka M, et al. Surg Today. 2024 Oct;54(10):1146-1153. doi: 10.1007/s00595-024-02811-3. Epub 2024 Mar 14. Surg Today. 2024. PMID: 38483630
Pulmonary artery occlusion post immunotherapy for hilar node-positive lung cancer.
Tada M, Uehara H, Ohyu T, Watanabe A. Tada M, et al. Thorac Cancer. 2023 Aug;14(22):2222-2224. doi: 10.1111/1759-7714.15001. Epub 2023 Jun 20. Thorac Cancer. 2023. PMID: 37337859 Free PMC article.
Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient.
Takamori S, Takenoyama M, Matsubara T, Fujishita T, Ito K, Yamaguchi M, Toyozawa R, Seto T, Okamoto T. Takamori S, et al. Thorac Cancer. 2020 Dec;11(12):3605-3608. doi: 10.1111/1759-7714.13697. Epub 2020 Oct 16. Thorac Cancer. 2020. PMID: 33063937 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations

Affiliations

Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical